WORLD LEADERS IN THE LAB DIAGNOSTICS MARKET, WE ARE SPECIALISTS IN THE IMMUNODIAGNOSTIC AND MOLECULAR DIAGNOSTIC SEGMENTS AND ACTIVE IN THE LICENSED TECHNOLOGY BUSINESS

We have been developing, producing and marketing reagent kits for laboratory diagnostics all over the world, for over 50 years. Our broad offering of diagnostic tests and Licensed Technology solutions, made available thanks to ongoing investments in research, positions us as the player with the widest range of specialty solutions in the sector and identifies the Group as the "Diagnostics Specialist".

Diagnosis is the first step towards understanding a person’s state of health. This is why our tests can make the difference: they are precise and reliable and enable delivery of early diagnosis of various pathologies for millions of people who will then be able to receive the most appropriate therapy.

Listed on the Italian Stock Exchange in the FTSE MIB Index
We market and develop diagnostic tests and solutions in the **immunodiagnostic** and **molecular diagnostic** sectors.

We offer technological and innovative solutions ranging from hospital and commercial analysis laboratories to decentralized contexts.

**IN VITRO DIAGNOSTICS**

**LICENSED TECHNOLOGIES**

We help scientists get quick and reliable responses to complex biological issues with an innovative and unique technology supporting different markets including biomedical research, genomic and proteomic research, clinical diagnostics and drug development.
The doctor prescribes **DIAGNOSTIC TESTS**

The patient has **SAMPLES** taken in a healthcare facility or analysis laboratory

The samples are univocally classified, labelled and **ANALYZED IN A LABORATORY**

In the laboratory, the samples are processed by **SPECIALIZED EQUIPMENT** that provides the diagnostic responses required on the basis of the reaction between the samples and the **DIAGNOSTIC TEST REAGENTS**

The outcome of the tests performed by the patient will allow the doctor to take the most correct therapeutic path

---

**1. LABORATORY DIAGNOSTICS**

- The doctor prescribes **DIAGNOSTIC TESTS**
- The patient has **SAMPLES** taken in a healthcare facility or analysis laboratory
- The samples are univocally classified, labelled and **ANALYZED IN A LABORATORY**
- In the laboratory, the samples are processed by **SPECIALIZED EQUIPMENT** that provides the diagnostic responses required on the basis of the reaction between the samples and the **DIAGNOSTIC TEST REAGENTS**

**2. POINT OF CARE DIAGNOSTICS**

- A patient goes into a **PHARMACY** to monitor a parameter or identify a pathology
- A healthcare operator **TAKES A SAMPLE AND PROCESSES THE TEST**
- **THE PLATFORM DELIVERS THE RESULT** to the patient in digital or paper format very quickly

**3. LICENSED TECHNOLOGIES**

- Healthcare sector clients need to **DEVELOP A NEW PRODUCT** (drug, test, vaccine, etc.)
- **DiaSorin provides the PLATFORM FOR RESEARCH AND THE TECHNOLOGY**
- The client initiates the **DEVELOPMENT AND RESEARCH PROCESS**
- **FINISHED PRODUCT LAUNCH**
DiaSorin, the diagnostics division of SORIN Group, is sold to the multinational American Standard International A management buyout brings DiaSorin ownership back to Italy On July 19, DiaSorin is listed on the Italian stock exchange (Piazza Affari, Milan) DiaSorin continues to grow organically and inorganically, expanding geographically and investing in technology and product innovation. It forms numerous partnerships with leading players in the global diagnostics market (Roche, Beckman Coulter, Meridian Bioscience) DiaSorin stock is included in the FTSE MIB DiaSorin enters a partnership with Qiagen for latent tuberculosis testing DiaSorin acquires Siemens Healthineers’ ELISA business DiaSorin enters the molecular diagnostic sector by acquiring the American Focus Diagnostics, now DiaSorin Molecular, adding to the Group’s competence and excellence DiaSorin signs an exclusive license agreement with TTP for the development of a molecular Point-of-Care (POC) solution Launch of 5 COVID tests

DiaSorin enters the molecular diagnostic sector by acquiring the American Focus Diagnostics, now DiaSorin Molecular, adding to the Group’s competence and excellence

DiaSorin enters a partnership with Qiagen for latent tuberculosis testing

DiaSorin signs an exclusive license agreement with TTP for the development of a molecular Point-of-Care (POC) solution

DiaSorin launches the LIAISON IQ analyzer with Lumos Diagnostics for Point-of-Care (POC) immunodiagnostics

DiaSorin enters a partnership with Qiagen for latent tuberculosis testing

DiaSorin acquires Siemens Healthineers’ ELISA business

DiaSorin signs an exclusive license agreement with TTP for the development of a molecular Point-of-Care (POC) solution

DiaSorin acquires the US company Luminex Corporation for $1.8bn, thus gaining multiplexing technology for molecular diagnostics and entering the Licensed Technology field

DiaSorin launches the Lyme test in partnership with QIAGEN and the MeMed BV test in partnership with MeMed
NORTH AMERICA
38% of Group Revenues
USA | Austin - Chicago - Cypress
Madison - Seattle - Stillwater
CANADA | Toronto

EUROPE
26% of Group Revenues
ITALY | Saluggia - Gerenzano
GERMANY | Dietzenbach
UK | Dartford

REST OF THE WORLD
14% of Group Revenues

NORTH AMERICA
38% of Group Revenues

EUROPE
26% of Group Revenues

REST OF THE WORLD
14% of Group Revenues

Data as of June 30, 2022

~3,350 Employees

COVID
22% of Group Revenues

R&D and Operations

Direct Presence

Countries served through distributors

CHINA | Shanghai FROM 2023
Financials

Data in € mln

Guidance FY 2022:
~1,3 €/mld at CER

Guidance FY 2022:
EBITDA Adjusted Margin at CER
~38%
Our business by tech

- **COVID**: 22%
- **Immunodiagnostics**: 49%
- **Licensed Technologies**: 15%
- **Molecular Diagnostic**: 14%

Data as of June 30, 2022
M&A & Partnerships

**PARTNERSHIPS**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Byk Sangtec</td>
<td>Biotrin</td>
<td>Murex</td>
<td>ENZYGNOST</td>
</tr>
<tr>
<td>(Abbott)</td>
<td></td>
<td>(Healthineers)</td>
<td></td>
</tr>
<tr>
<td>CLIA immunodiagnostic platform</td>
<td>Parvovirus</td>
<td>ELISA Hepatitis &amp; Retrovirus</td>
<td>Molecular Diagnostics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Molecular Diagnostics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ELISA Business</td>
<td></td>
</tr>
</tbody>
</table>

M&A

**Connectivity for lab automation**

**Hepatitis & Retrovirus**

**QuantiFERON Technology**

**Molecular Point-of-Care (POC) Platform**

**Immunodiagnostics Point-of-Care (POC) Platform**

**Bacterial vs. Viral infection testing**
Our Immunodiagnostic Systems

LIAISON® IQ
LIAISON® XS
LIAISON® XL/ XL LAS
LIAISON® XXL*

NEAR-PATIENT
SMALL-TO-MEDIUM LABS
MEDIUM-TO-LARGE LABS

CLINICAL AREAS
- Infectious diseases
- Autoimmunity
- Bone & mineral
- Endocrinology
- Hypertension
- Oncology
- Stool diagnostics

* To be launched
Our Molecular Diagnostic Systems

**NEAR PATIENT**
- LIAISON® NES*
- ARIES®
- LIAISON® MDx
- LIAISON® MDx Plus*

**SINGLE-LOW PLEX PLATFORMS**
Detected the presence of up to 5 pathogen agents starting from a single sample

**NON-AUTOMATED**
- Luminex® 100/200
- MAGPIX®
- Verigene®
- LIAISON® Plex*

**AUTOMATED**

**MULTIPLEXING PLATFORMS**
Simultaneously detects the presence of up to 40 different pathogens from a single sample

**CLINICAL AREAS**
- Respiratory Infections
- Herpes viruses
- Meningitis/Encephalitis
- Hospital Acquired Infections
- Vector borne
- Bloodstream Infections
- Transplant
- Women's/Neonatal Health
- Genetics/Cystic Fibrosis

*To be launched*
Our Licensed Technologies Systems

**LICENCED TECHNOLOGIES GROUP**

- Luminex® 100/200
- FLEXMAP 3D®
- MAGPIX®
- xMAP® INTELLIFLEX
- Guava® Muse®
- Guava® easyCyte™ / HT
- Amnis® CellStream®
- ImageStream® Mk II
- Amnis FlowSight®

**FLOW CYTOMETRY**

**MAIN APPLICATIONS**
- Allergy Testing
- Alzheimer
- Autoimmune Disease
- Biodefense/Environmental
- Cancer Markers
- Cardiac Markers
- Cellular Signaling
- Cytokines, Chemokines and Growth Factors
- Endocrine
- Gene Expression Profiling
- Genotyping
- HLA Testing
- Immunogenicity
- Infectious Disease
- Isotyping
- Matrix Metalloproteinase
- Metabolic Markers
- Neurobiology/Brain and Nervous System Markers
- Plant & Food Safety
- Sepsis Markers
- Transcription Factors/Nuclear Receptors
- Toxicology
- Vaccine Testing

**MAIN APPLICATIONS**
- Cell Health
- Cell Pathways
- Autophagy
- Immunology
- Malaria Research
- Cell Absolute Counting
- Small Particle detection
- Immunological Phenotyping
- Advanced Phenotyping & Analysis
- Cell Function & Mechanism
- Statistical microscopy applications